Home | News |

UC-Davis selected as a site for the NeuroNEXT Network for Excellence in Neuroscience Clinical Trials

The National Institute of Neurological Disorders and Stroke (NINDS) has selected UC Davis Health System to be one of 25 clinical sites in the United States, and one of just four on the West Coast, in its newly created NeuroNEXT Network for Excellence in Neuroscience Clinical Trials. 

The network is designed to support high-quality clinical trials over the next seven years for neurological disorders ranging from brain injury, multiple sclerosis and stroke to dementias, neuromuscular diseases, movement disorders and autism. The new network also will leverage the health system's major research and clinical care strengths in neurosciences and make new treatment protocols available in the region.

We have an unprecedented set of tools for making clinical trials more efficient, getting results more rapidly and, ultimately, enabling them to bring innovative and effective treatments to people with debilitating disorders.

Click here to visit the UC Davis Network for Excellence in Neuroscience Clinical Trials web site

The UC Davis web page contain information and links that will enable prospective researchers, even those with limited experience in conducting studies, to have their proposals seriously considered and supported. Being part of the new network offers access to clinical trials participants at locations beyond the Sacramento region. It offers a central institutional review board function, which can greatly reduce time and speed up the review process. It provides a centralized coordinating center for such things as contracts and trial design, as well as a centralized data coordinating center for implementing clinical trials at different locations.

The network's advantages include the following:

  • Designed to expand the pool of experienced clinical researchers and staff
  • Provides a complete, standardized and accessible clinical trials infrastructure
  • Supports scientifically sound, phase 2 clinical trials, possibly biomarker-informed
  • Leverages federal, industry, foundation and patient advocacy partners to organize phase 2 trials
  • Offers access to participants from multiple clinic sites, as well as access to a centralized system protocol review and approval and data coordination.